Company Overview of Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in North America. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis...
1901 North Roselle Road
Schaumburg, IL 60195
Founded in 2006
Key Executives for Sagent Pharmaceuticals, Inc.
President, Chief Legal Officer and Corporate Secretary
Total Annual Compensation: $328.9K
Chief Financial Officer and Executive Vice President
Total Annual Compensation: $344.8K
Executive Vice President of National Accounts & Corporate Development
Total Annual Compensation: $297.1K
Compensation as of Fiscal Year 2014.
Sagent Pharmaceuticals, Inc. Key Developments
Sagent Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Reaffirms Earnings Guidance for the Year Ending December 31, 2015
Nov 3 15
Sagent Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. Net revenue for the third quarter of 2015 was $75.2 million, an increase of $9.8 million, or 15%, compared to $65.4 million in the third quarter of 2014. The increase was driven by the $7.3 million from the addition of Omega on October 1, 2014 and the contribution from the launch of new products since September 30, 2014. Adjusted EBITDA for the third quarter of 2015 was $8.8 million, an increase of $1.5 million, or 21% compared to $7.2 million in the third quarter of 2014. The increase in adjusted EBITDA is primarily driven by the increase in adjusted gross profit, offset by the increase in product development expense due to the timing of milestone payments. The net loss for the three months ended September 30, 2015 was $1.8 million, compared to net income of $1.9 million in the third quarter of 2014. EBITDA was $2.681 million against $5.173 million a year ago. The company reported income from operations of $1.742 million compared to $4.044 million, loss before income taxes of $0.132 million compared to profit before income taxes of $3.313 million, net loss of $1.795 million or $0.05 per diluted share compared to net income $1.926 million or $0.06 per diluted share.
For the nine months, the company reported revenue of $235.188 million compared to $205.422 million, income from operations of $2.743 million compared to $13.994 million, Loss before income taxes of $0.132 million compared to profit before income taxes of $12.888 million, net loss of $3.945 million or $0.12 per diluted share compared to net income of $10.114 million or $0.31 per diluted share and adjusted EBITDA of $24.058 million compared to $23.956 million for the last year. EBITDA was $9.183 million against $19.427 million a year ago.
For the year ending December 31, 2015, the company expects net revenue for the year to be in the range of $305 to $330 million; adjusted gross profit as a percentage of net revenue in the range of 25% to 28%; and operating expenses in the range of $80 to $90 million. Based on the above assumptions, the company anticipates adjusted EBITDA in the range of $20 - $30 million. EBITDA expected to be in the range of $10 to $18 million. Depreciation and amortization expense are expected to be in the range of $12 to $16 million.
Sagent Pharmaceuticals Introduces Chlorothiazide Sodium for Injection
Oct 29 15
Sagent Pharmaceuticals announced that it has introduced Chlorothiazide Sodium for Injection, USP, a diuretic/antihypertensive agent, in a 500 mg preservative-free, single-dose vial. The product features the company's PreventIV MeasuresSM Packaging and Labelling, aimed at helping decrease the risk of medication errors. The product is indicated as an adjunctive therapy in oedema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Sagent Pharmaceuticals, Inc. to Report Q3, 2015 Results on Nov 03, 2015
Oct 20 15
Sagent Pharmaceuticals, Inc. announced that they will report Q3, 2015 results at 9:00 AM, US Eastern Standard Time on Nov 03, 2015
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|